References
- Gupta RS. The prevalence, severity, and distribution of childhood food allergy in the United States. Pediatrics. 2011 July;128(1): e9–17.
- Gupta RS, Warren CM, Smith BM, et al. Prevalence and severity of food allergies among US adults. JAMA Netw Open. 2019;2(1):e185630.
- DunnGalvin A, Blumchen K, Timmermans F, et al. APPEAL-1: a multiple-country European survey assessing the psychosocial impact of peanut allergy. Allergy. 2020(April):1–10. DOI:10.1111/all.14363
- Sicherer SH, Noone SA, Munoz-Furlong A. The impact of childhood food allergy on quality of life. Annals of Allergy, Asthma & Immunol. 2001;87. DOI:10.1016/S1081-1206(10)62258-2
- Anagnostou K. Food immunotherapy for children with food allergies: state of the art and science. Curr Opin Pediatr. 2018;30:798–805.
- Vickery BP, Vereda A, Casale TB, et al. AR101 oral immunotherapy for peanut allergy. N Engl J Med. 2018:379;1991–2001. DOI:10.1056/NEJMoa1812856
- Mack DP, Greenhawt M, Turner PJ, et al. Information needs of patients considering oral immunotherapy for food allergy. Clin Exp Allergy. 2022;52:1391–1402.
- Anagnostou K, Islam S, King Y, et al. Assessing the efficacy of oral immunotherapy for the desensitisation of peanut allergy in children (STOP II): a phase 2 randomised controlled trial. Lancet. 2014:383(9925);1297–1304. DOI:10.1016/S0140-6736(13)62301-6
- Anagnostou K, Clark A, King Y, et al. Efficacy and safety of high-dose peanut oral immunotherapy with factors predicting outcome. Clin Exp Allergy. 2011;41. DOI:10.1111/j.1365-2222.2011.03699.x
- Begin P, Winterroth LC, Dominguez T, et al. Safety and feasibility of oral immunotherapy to multiple allergens for food allergy. Allergy, Asthma Clin Immunol. 2014;10. DOI:10.1186/1710-1492-10-1
- Andorf S, Purington N, Kumar D, et al. A phase 2 randomized controlled multisite study using omalizumab-facilitated rapid desensitization to test continued vs discontinued dosing in multifood allergic individuals. Lancet. 2019;7:27–38.
- Vickery BP, Berglund JP, Burk CM, et al. Early oral immunotherapy in peanut-allergic preschool children is safe and highly effective. J Allergy Clin Immunol. 2017:139;173–181.e8. DOI:10.1016/j.jaci.2016.05.027
- Jones SM, Kim EH, Nadeau KC, et al. Efficacy and safety of oral immunotherapy in children aged 1–3 years with peanut allergy (the immune tolerance network IMPACT trial): a randomised placebo-controlled study. Lancet. 2022:399(10322);359–371.DOI: 10.1016/s0140-6736(21)02390-4
- Anagnostou A, Hourihane JOB, Greenhawt M. The role of shared decision making in pediatric food allergy management. J Allergy Clin Immunol Pract. 2019;46–51. DOI:10.1016/j.jaip.2019.09.004
- Greenhawt M, Shaker M, Winders T, et al. Development and acceptability of a shared decision-making tool for commercial peanut allergy therapies. Annals of Allergy, Asthma & Immunol. 2020 Feb. DOI:10.1016/j.anai.2020.01.030